XML 89 R15.htm IDEA: XBRL DOCUMENT
v3.20.1

Major Customers and Concentration of Credit Risk | 12 Months Ended
--- | ---
Dec. 31, 2019
Risks and Uncertainties [Abstract] |
Major Customers and Concentration of Credit Risk | Major Customers and Concentration of Credit Risk
Customer | 2019 Revenue |  | % of Total Revenue |  | 2018 Revenue |  | % of Total Revenue |  | 2017 Revenue |  | % of Total Revenue
ApolloBio | $ | — |  |  | — | % |  | $ | 23,000,000 |  |  | 75 | % |  | $ | — |  |  | — | %
AstraZeneca | 3,194,877 |  |  | 78 |  |  | 6,850,424 |  |  | 23 |  |  | 22,269,773 |  |  | 53 |
DARPA | — |  |  | — |  |  | — |  |  | — |  |  | 9,983,927 |  |  | 24 |
Roche | — |  |  | — |  |  | — |  |  | — |  |  | 6,107,254 |  |  | 14 |
All other, including affiliated entities | 917,053 |  |  | 22 |  |  | 631,473 |  |  | 2 |  |  | 3,859,132 |  |  | 9 |
Total revenue | $ | 4,111,930 |  |  | 100 | % |  | $ | 30,481,897 |  |  | 100 | % |  | $ | 42,220,086 |  |  | 100 | %
During the years ended December 31, 2019 and 2018, the Company recognized revenue from various license fees and collaborative research and development agreements. The Company has determined that as of January 1, 2018, accounting for the Company’s various grant agreements falls under the contributions guidance under Subtopic 958-605, Not-for-Profit Entities-Revenue Recognition, which is outside the scope of Topic 606. Beginning on January 1, 2018, all contributions received from current grant agreements have been recorded as a contra-expense as opposed to revenue on the consolidated statements of operations, as discussed in Note 2. During the year ended December 31, 2017, the Company recognized revenue from various license fees, collaborative research and development agreements, grants and government contracts. As of December 31, 2019, $469,000, or 67%, and $161,000, or 23%, of the Company's accounts receivable was attributable to MCDC and AstraZeneca, respectively. As of December 31, 2018, $3.2 million, or 98%, of the Company's accounts receivable was attributable to AstraZeneca. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration